{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:19:23Z","timestamp":1787854763529,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015502","name":"Dialysis Clinics","doi-asserted-by":"publisher","award":["C-4222"],"award-info":[{"award-number":["C-4222"]}],"id":[{"id":"10.13039\/100015502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07897-0","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:14:05Z","timestamp":1783059245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease"],"prefix":"10.1007","author":[{"given":"Parth","family":"Dhamelia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninad","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Vallurupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Saucedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmik","family":"Jadvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Beemidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishank","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"7897_CR1","unstructured":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/32061315\/. Accessed Nov 29, 2025."},{"key":"7897_CR2","doi-asserted-by":"publisher","unstructured":"Chang DR, Chiang H, Hsiao Y et al. Interaction between chronic kidney disease and atrial fibrillation on incident stroke and all-cause mortality: Matched cohort study of 49,594 patients. Atherosclerosis. 2025;401:119055. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021915024012279. Accessed Dec 15, 2025. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119055","DOI":"10.1016\/j.atherosclerosis.2024.119055"},{"issue":"1","key":"7897_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCEP.110.957100","volume":"4","author":"U Baber","year":"2011","unstructured":"Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the united states: Reasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysiol. 2011;4(1):26\u201332. https:\/\/doi.org\/10.1161\/CIRCEP.110.957100. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3049935\/. Accessed Jan 5, 2026.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"7897_CR4","doi-asserted-by":"publisher","unstructured":"Joglar JA, Chung MK, Armbruster AL et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the american college of cardiology\/american heart association Joint Committee on Clinical practice guidelines. J Am Coll Cardiol. 2024;83(1):109\u2013279. https:\/\/pubmed.ncbi.nlm.nih.gov\/38043043\/. Accessed Dec 9, 2025. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.017","DOI":"10.1016\/j.jacc.2023.08.017"},{"key":"7897_CR5","doi-asserted-by":"crossref","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analysis. BMJ. 2016;354(i4482). https:\/\/doi.org\/10.1136\/bmj.i4482. https:\/\/www.bmj.com\/content\/354\/bmj.i4482. Accessed Dec 9, 2025.","DOI":"10.1136\/bmj.i4482"},{"issue":"8","key":"7897_CR6","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/ndt\/gfq106","volume":"25","author":"KR Wilund","year":"2010","unstructured":"Wilund KR, Tomayko EJ, Wu P, et al. Intradialytic exercise training reduces oxidative stress and epicardial fat: A pilot study. Nephrol Dial Transpl. 2010;25(8):2695\u2013701. https:\/\/doi.org\/10.1093\/ndt\/gfq106. https:\/\/pubmed.ncbi.nlm.nih.gov\/20190243\/. Accessed Dec 17, 2025.","journal-title":"Nephrol Dial Transpl"},{"key":"7897_CR7","doi-asserted-by":"publisher","unstructured":"Kerr JD, Holden RM, Morton AR et al. Associations of epicardial fat with coronary calcification, insulin resistance, inflammation, and fibroblast growth factor-23 in stage 3\u20135 chronic kidney disease. BMC Nephrol. 2013;14:26. https:\/\/pubmed.ncbi.nlm.nih.gov\/23351146\/. Accessed Dec 17, 2025. https:\/\/doi.org\/10.1186\/1471-2369-14-26","DOI":"10.1186\/1471-2369-14-26"},{"issue":"4","key":"7897_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","volume":"117","author":"D Ding","year":"2021","unstructured":"Ding D, WY, Gupta, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117(4):1046\u201359. https:\/\/doi.org\/10.1093\/cvr\/cvaa258. https:\/\/pubmed.ncbi.nlm.nih.gov\/32871005\/. Accessed Jan 5, 2026.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"7897_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347. https:\/\/pubmed.ncbi.nlm.nih.gov\/38785209\/. Accessed Nov 29, 2025.","journal-title":"N Engl J Med"},{"issue":"4","key":"7897_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"DJ Drucker. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001. https:\/\/pubmed.ncbi.nlm.nih.gov\/29617641\/. Accessed Nov 29, 2025.","journal-title":"Cell Metab"},{"key":"7897_CR11","doi-asserted-by":"publisher","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305. Accessed Dec 9, 2025.","DOI":"10.1001\/jamanetworkopen.2024.21305"},{"key":"7897_CR12","doi-asserted-by":"publisher","unstructured":"Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z. Accessed Dec 17, 2025.","DOI":"10.1038\/s41392-024-01931-z"},{"key":"7897_CR13","doi-asserted-by":"publisher","unstructured":"Kramer CM, Borlaug BA, Zile MR et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related Heart Failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85(7):699\u2013706. https:\/\/pubmed.ncbi.nlm.nih.gov\/39566869\/. Accessed Dec 15, 2025. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001","DOI":"10.1016\/j.jacc.2024.11.001"},{"key":"7897_CR14","doi-asserted-by":"publisher","unstructured":"Agarwal R, Green JB, Heerspink HJL et al. Impact of baseline GLP-1 receptor agonist use on albuminuria reduction and safety with simultaneous initiation of finerenone and empagliflozin in type 2 diabetes and chronic kidney disease (CONFIDENCE trial). Diabetes Care. 2025;48(11):1904\u20131913. https:\/\/doi.org\/10.2337\/dc25-1673. Accessed Dec 15, 2025.","DOI":"10.2337\/dc25-1673"},{"key":"7897_CR15","unstructured":"Annual data reporthttps:\/. \/usrds-adr.niddk.nih.gov\/. Accessed Dec 16, 2025."},{"key":"7897_CR16","unstructured":"Real-world data for the life sciences. and healthcarehttps:\/\/trinetx.com\/. Accessed Dec 9, 2025."},{"key":"7897_CR17","doi-asserted-by":"publisher","unstructured":"Ludwig RJ, Anson M, Zirpel H et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol. 2025;16:1516126. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11931024\/. Accessed Dec 9, 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1516126","DOI":"10.3389\/fphar.2025.1516126"},{"key":"7897_CR18","doi-asserted-by":"publisher","unstructured":"Palchuk MB, London JW, Perez-Rey D et al. A global federated real-world data and analytics platform for research. Jama Open. 2023;6(2):ooad035. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035. Accessed Dec 9, 2025. doi: 10.1093\/jamiaopen\/ooad035.","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"7897_CR19","doi-asserted-by":"publisher","unstructured":"Chuang M, Chen J, Wang H, Jiang Z, Wu V. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024;7(8):e2427258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27258. Accessed Dec 9, 2025. doi: 10.1001\/jamanetworkopen.2024.27258.","DOI":"10.1001\/jamanetworkopen.2024.27258"},{"issue":"11","key":"7897_CR20","first-page":"1814","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, et al. GLP-1 receptor agonists among Patients With overweight or obesity, diabetes, and HFpEF on SGLT2 Inhibitors. JACC: Heart Fail. 2024;12(11):1814\u201326. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.006. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213177924005614. Accessed Dec 15, 2025.","journal-title":"JACC: Heart Fail"},{"key":"7897_CR21","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chinchilli VM, Ssentongo P, Ba DM. Association of long COVID with mental health disorders: A retrospective cohort study using real-world data from the USA. BMJ Open. 2024;14(2). https:\/\/bmjopen.bmj.com\/content\/14\/2\/e079267. Accessed Dec 15, 2025. https:\/\/doi.org\/10.1136\/bmjopen-2023-079267","DOI":"10.1136\/bmjopen-2023-079267"},{"key":"7897_CR22","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England J Med. 2023;389(24):2221\u20132232. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2307563. Accessed Dec 9, 2025. https:\/\/doi.org\/10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"7897_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/CLEP.S438096","volume":"16","author":"T Bothe","year":"2024","unstructured":"Bothe T, Fietz A, Schaeffner E, et al. Diagnostic validity of chronic kidney disease in health claims data over time: Results from a cohort of community-dwelling older adults in germany. Clin Epidemiol. 2024;16:143\u201354. https:\/\/doi.org\/10.2147\/CLEP.S438096. https:\/\/pubmed.ncbi.nlm.nih.gov\/38410416\/. Accessed Dec 9, 2025.","journal-title":"Clin Epidemiol"},{"key":"7897_CR24","unstructured":"New study finds GLP-1. receptor agonists may reduce atrial fibrillation-related events in patients with obesity - HRS. https:\/\/www.hrsonline.org\/news\/glp1-study-reduces-afib-events\/. Accessed Dec 9, 2025."},{"issue":"9","key":"7897_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606. https:\/\/doi.org\/10.1038\/s41569-022-00679-9. https:\/\/pubmed.ncbi.nlm.nih.gov\/35296869\/. Accessed Dec 9, 2025.","journal-title":"Nat Rev Cardiol"},{"key":"7897_CR26","doi-asserted-by":"publisher","unstructured":"Bidirectional association between kidney function and atrial fibrillation. A Population-Based cohort study | journal of the american heart association. https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/JAHA.122.025303. Accessed Nov 29, 2025.","DOI":"10.1161\/JAHA.122.025303"},{"key":"7897_CR27","doi-asserted-by":"publisher","unstructured":"Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017;25(2):311\u2013316. https:\/\/pubmed.ncbi.nlm.nih.gov\/28124506\/. Accessed Dec 15, 2025. https:\/\/doi.org\/10.1002\/oby.21718","DOI":"10.1002\/oby.21718"},{"key":"7897_CR28","doi-asserted-by":"publisher","unstructured":"Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471\u20132477. https:\/\/pubmed.ncbi.nlm.nih.gov\/15562125\/. Accessed Jan 5, 2026. https:\/\/doi.org\/10.1001\/jama.292.20.2471","DOI":"10.1001\/jama.292.20.2471"},{"key":"7897_CR29","doi-asserted-by":"publisher","unstructured":"Chen P, Yang F, Wang W et al. Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-mediated ROS production in hypertensive mice. J Cardiovasc Pharmacol Ther. 2021;26(2):179\u2013188. https:\/\/pubmed.ncbi.nlm.nih.gov\/32686479\/. Accessed Dec 17, 2025. https:\/\/doi.org\/10.1177\/1074248420942007","DOI":"10.1177\/1074248420942007"},{"issue":"5, Supplement","key":"7897_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5, Supplement):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0085253822005075. Accessed Dec 9, 2025.","journal-title":"Kidney Int"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07897-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:14:18Z","timestamp":1783059258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07897-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":30,"alternative-id":["7897"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07897-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The funder\/sponsor did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of data; or the preparation, review, and decision to submit manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of Funder\/Sponsor Statement"}},{"value":"We thank the UAMS Science Communication Group for reviewing the manuscript without compensation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-Author Contributions to Data Collection, Analysis, or Writing\/Editing Assistance"}},{"value":"All information and materials in the manuscript are original.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Originality of Content"}}]}}